MoGlimaging

Principal investigators: ELIZABETH COHEN-JONATHAN MOYAL & CHRISTINE TOULAS

Modeling of Glioblastoma treatment-induced resistance & heterogeneity by multi-modal imaging

8 teams working on Glioblastoma (GBM), the most aggressive brain tumor, collaborate to model GBM heterogeneity and treatment resistance. They follow three research lines with the final objective to predict patient response to treatments.

Representative confocal images showing intercellular connections by tunnel nanotubes in neuronal CAD cell line (from Delage et al., Sci Rep. 2016)

The network studies the involvement of cellular plasticity, cell/cell interactions, migratory capacities, microenvironment in GBM heterogeneity response to treatment focusing particularly on in vitro tunneling-nanotubes formations on patients stem cells and differentiated cells.

Fingerprints of 4 glioma rat models and of healthy tissue, obtained by MRH (from 5 HRI parameters: Diffusion, Blood volume, permeability, vessel size and oxygenation)

The second line is the study of GBM heterogeneity in vivo not only on animal models by magnetic resonance histology (MRH) but also with multimodal imaging data of patients.

Evaluation of the prediction obtained from the model of 58 patients

A modeling of tumor heterogeneity and treatment – resistance defined by multi-modal imaging in GBM patients (clinical trial STEMRI) and animal models from two first research lines is performed in order to develop mathematical models for predicting the response to treatment. 

This model of prediction of response to treatment will then allow the network to design, after validation in preclinical in vivo assays, clinical trials associating specific inhibitor of the pathways controlling the specific type of recurrence with radio-chemotherapy in GBM patients routinely followed by multimodal magnetic resonance imagery

This French program is organized by ITMO Cancer, in collaboration with ITMO BCDE (Cell Biology, Development and Evolution) and ITMO Technologies for Health of the National Alliance for Life Sciences and Health (AVIESAN) with the National Cancer Institute (INCA) and Inserm within the framework of the Cancer Plan. Operational management is entrusted to Inserm.
It was launch in order to develop a critical mass of resources and skills in order to conduct interdisciplinary research projects in the field of functional heterogeneity of cellular tumor relations in their ecosystem: the "HTE Program".

Initiation of HTE Program